Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Property, Plant & Equipment (Net)

Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Property, Plant & Equipment (Net) · Q2 FY2026 · quarter ended Jun 2026

Property, plant & equipment (net) of $6.92M in Q2 FY2026

Q2 FY2026 property, plant & equipment (net) was $6.92M.

Context

  • Property, plant & equipment (net) amounted to 5.4% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6.92M-7.6% QoQ
Last fiscal yearDec 2025
$7.87M+143.2% YoY
Property, Plant & Equipment (Net) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+143.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Property, Plant & Equipment (Net) history

USD · from the balance sheet

Latest · FY2025
7.87M USD
Year-over-year change
+143.2%
1-year CAGR
+143.2%

Property, Plant & Equipment (Net) vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
  • Property, plant & equipment (net) amounts to 5.4% of total assets for ATTO, versus a peer median of 2.2%.
ATTO Competitors
Property, Plant & Equipment (Net) for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALMSAlumis Inc. Common StockJun 2026$34.12M USD-11.5%+98.8%6.1%
ANABAnaptysBio, Inc.Mar 2026$13.32M USD-15.0%-11.4%4.0%
EVMNEvommune, Inc.Mar 2026$9.57M USD+573.5%—3.0%
ATTOAttovia Therapeutics, Inc.Jun 2026$6.92M USD——5.4%
QTTBQ32 Bio Inc.Mar 2026$5.83M USD-14.6%-12.8%9.1%
CNTBConnect Biopharma Holdings LimitedDec 2025$4.46M USD+5.1%-6.1%7.9%
ORKAOruka Therapeutics, Inc.Sep 2026$3.1M USD+39.3%+79.2%0.3%
ACRSAclaris Therapeutics, Inc.Mar 2026$2.89M USD+206.5%—1.5%
MLTXMoonLake ImmunotherapeuticsMar 2026$2.39M USD-27.6%+86.2%0.6%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€1.68M EUR——1.0%
ZURAZura Bio LimitedMar 2026$125K USD+17.9%—0.1%
Peer median (excluding ATTO) —+5.1%+36.6%2.2%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.